Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
These findings suggest that temporary interruption and continuation of IA result in similar risk and outcome of infections in IRD patients. Although his study is limited by low statistical power, the findings suggest that continuation of IA during an infection is safe.
Authors
- Reinout van Crevel
- Alfons A den Broeder (ORCID: https://orcid.org/0000-0002-9012-4079)
- M. Opdam (ORCID: https://orcid.org/0000-0003-3385-8807)
- Lise M Verhoef (ORCID: https://orcid.org/0000-0002-9740-5607)
- Léon Raymakers (ORCID: https://orcid.org/0009-0000-1530-8786)
- Lisa Schapink (ORCID: https://orcid.org/0000-0001-7999-4711)
- Nathan den Broeder (ORCID: https://orcid.org/0000-0001-7126-2209)
- Jasper Broen (ORCID: https://orcid.org/0000-0002-4344-3157)
Institutions
- Radboud University Nijmegen (NL)
- University Medical Center (US)
- Radboud University Medical Center (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Máxima Medisch Centrum (NL)
- Sint Maartenskliniek (NL)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1093/cid/ciaf442
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Gilead Sciences
- Biogen
- Celltrion